Black Diamond Therapeutics, Inc. — 2019 Form 10-K Summary
Business context and reporting period
For the fiscal year ended December 31, 2019. Black Diamond is a pre-revenue precision oncology company developing small-molecule therapies for genetically defined cancers using its Mutation-Allostery-Pharmacology (MAP) platform. Its lead candidate, BDTX-189, targets selected EGFR and HER2 mutations.
The FDA allowed the BDTX-189 IND in December 2019. The company reported that Phase 1 enrollment and dosing had begun; the filing describes a planned Phase 1/2 tumor-agnostic program. The IPO closed February 3, 2020, after the reporting year.
Financial performance and liquidity
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $21.8 million | $7.0 million |
| General and administrative expense | $7.6 million | $2.0 million |
| Total operating expenses / operating loss | $29.3 million | $8.9 million |
| Net loss | $35.3 million | $8.9 million |
| Net loss per share, basic and diluted | $16.99 | $4.42 |
| Cash used in operating activities | $24.7 million | $8.5 million |
For Q4 2019, operating expenses were $10.3 million and net loss was $9.9 million; quarterly revenue was zero. Gross margin is not applicable because the company had no revenue or product sales.
At year-end, cash and cash equivalents were $154.7 million; current assets were $155.7 million and current liabilities $4.9 million. The company reported $4.9 million total liabilities, including $16,000 of derivative liabilities, and no conventional borrowings outstanding on the balance sheet. Convertible notes had previously converted into preferred stock. Preferred stock of $200.6 million was presented outside stockholders’ deficit. Accumulated deficit was $51.0 million.
Operating cash use rose year over year as research and development and headcount expanded. Financing provided $127.8 million in 2019, primarily from preferred stock issuance. The February 2020 IPO generated $231.3 million gross and $212.4 million net proceeds. Management expected year-end cash plus IPO proceeds to fund operations into 2023, subject to assumptions and development costs.
Material changes versus the prior year
- Net loss increased to $35.3 million from $8.9 million, reflecting sharply higher R&D and G&A spending as the company advanced BDTX-189 and expanded operations.
- Operating cash use increased to $24.7 million from $8.5 million; year-end cash rose to $154.7 million from $51.7 million, mainly following preferred stock financings.
- A $6.4 million non-cash loss from remeasurement of derivative liabilities affected 2019 results; the Series B tranche right was exercised in August 2019.
- The February 2020 IPO converted preferred shares into common stock and materially expanded liquidity after the balance-sheet date.
Outlook, risks and unusual items
- Management planned to complete BDTX-189 Phase 1 dose escalation in the first half of 2021 and anticipated selecting a glioblastoma development candidate in 2020. These are plans, not guaranteed outcomes. Accelerated approval would depend on clinical results and FDA agreement.
- The company expected increasing R&D and public-company costs, had no product revenue, and anticipated further financing needs beyond its stated runway.
- Clinical and regulatory risks include failure to show safety or efficacy in humans, small mutation-defined patient populations, enrollment delays, companion-diagnostic development, and uncertainty over tumor-agnostic approval.
- Black Diamond relied on third-party manufacturers and CROs, and had no manufacturing facilities. It was transitioning research and development services from related party Ridgeline Therapeutics; 2019 service fees were $10.4 million. Ridgeline is affiliated with a major shareholder and company directors.
- The company disclosed unremediated material weaknesses in internal control over financial reporting, ineffective disclosure controls, and a prior restatement of 2017 financial statements. Remediation work was underway.
- Its patent portfolio was early-stage, with patent applications but no issued patents covering BDTX-189, the MAP platform, or the glioblastoma program. No material legal proceedings were reported.
- The filing identified the emerging coronavirus outbreak as a potential source of disruption to research, suppliers, clinical sites, and trial enrollment.
Important facts for investors to verify
- Subsequent clinical progress and safety, tolerability, dose, and efficacy data for BDTX-189, including results by mutation and tumor type.
- Actual cash, burn rate, and runway after the IPO, compared with management’s projection into 2023.
- Progress on glioblastoma candidate selection and other MAP-platform programs.
- Whether internal-control material weaknesses are fully remediated and whether financial reporting remains reliable.
- Terms, costs, and governance of the Ridgeline transition, and the development and protection of the company’s patent portfolio.